Thyroid eye disease (TED) therapy Tepezza – the highest asset in Amgen's $26 billion takeover of Horizon in 2023 – may very well be struggling with Levels of competition from an easier-to-dose option from Sling Therapeutics. The inflammation can force the eyes forward or trigger t